BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. Microglia release BDNF that may contribute to neuroinflammation and neuropathic pain. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Less than 0.1% cross-reactivity against NGF, recombinant NT3 and NT4 by dot blot.
Application Information:
IHC, ELISA (1 site), Western Blot, immunoblot, inhibition of biological activity in vitro/in vivo. Recommended to be used at an amount of 1-10 µg/ml for immunohistochemistry, Western blot or immunoblot, 0.1 µg/ml for ELISA and for inhibition of biological activity in vitro 1-10 µg/ml. Use neat for in vivo studies at 2-10 µg/ml (ED50). This antiserum stains cell bodies and some nerve terminals in the dorsal horn of the rat spinal cord, however, does not stain finest nerve terminals.
Western blot: 1-10 ug/mL. Tissue homogenate is a recommended sample application for Western Blotting. The antibody detects 14 kDa (mature BDNF), 32 kDa (proBDNF) and a 18 kDa BDNF isoform, however numerous other non-characterized bands may also be present. In cell lysates, only 18 kDa and 32 kDa BDNF are detected. Alternative antibodies for Western Blotting are: R-1707-100 (cell lysates and tissue homogenates), R-083-100/R-066-500 (cell lysates, tissue homogenates and human serum); M-1744-50/100 (human serum and tissue homogenates).
Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Type: Primary
Antigen: rh BDNF
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope: Multiple points of reactivity likely because of the polyclonal nature of the antibody
Host: Rabbit
Isotype: IgG
Reactivity: Rat, Mouse, Human
